Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The tumor cell TRAIL pathway is a signaling cascade initiated by the binding of TRAIL to its receptors on tumor cells, leading to apoptosis. It is a key mechanism for inducing apoptosis selectively in cancer cells, while sparing most normal cells, making it an attractive target for cancer therapy. The pathway involves TRAIL, death receptors DR4 and DR5, decoy receptors DcR1, DcR2, and OPG, adaptor protein FADD, and caspases. Resistance to TRAIL-induced apoptosis can arise from upregulation of decoy receptors, overexpression of FLIP proteins, or activation of pro-survival pathways. Therapeutic strategies include recombinant TRAIL proteins and agonistic antibodies targeting DR4/DR5.
Activation of death receptors (DR4/DR5) leading to caspase activation and apoptosis.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) pathway (TRAIL pathway).